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The possible percutaneous absorption of mutagens 
from patients receiving crude coal tar (CCT) and ultra-
violet light was investigated. Urine samples were col-
lected from nonsmoking volunteers, smoking, and non-
smoking psoriatic patients. Patients were treated with 
1 % CCT U.S.P. or 1 to 10% CCT in petrolatum in the 
evening. The following morning, patients received coal 
tar baths and then ultraviolet light (mainly 290-320 nm, 
UVB). Nonpolar organics in urine samples were ex-
tracted by adsorption onto XAD-2 resin and the ex-
tracted organics assayed ill the Ames Salmonella/Micro-
some test. TA98 was the most sensitive bacterial strain 
to detect mutagenicity. Except for smoking psoriatic 
patients, the addition of liver homogenate was necessary 
to see mutagenicity. No increase in the number of re-
vertants was observed when B-glucuronidase was added 
to the assay. Of 14 patients studied 12 had at least one 
mutagenic urine sample. Typical values for nonsmoking 
psoriatics treated with CCT ranged from 42 to 496 
his + /20 ml of urine after the subtraction of spontaneous 
his + counts (26 ± 6). Two nonsmoking normal volunteers 
were found to excrete mutagenic urines. Smoking pso-
riatic patients ranged from 213 to 1,100 his + /20 ml 
urine. This study demonstrates the percutaneous ab-
sorption of mutagens from CCT and indicates that its 
effects may not be limited to the skin. 
The Goeckerman r egimen is considered an effective form of 
therapy for psoriasis [1). This treatment involves the applica-
tion of coal tar o intment to the skin followed by exposure of the 
s kin to ult ra violet light. 
Coal tar and many of its components are carcinogenic in 
animal bioassays [2,3)' The incidence of skin cancer in psoriatics 
does not a ppear to be higher than in the rest of the population 
[4,5]. Epidemiological studies of specific cancer incidence rates 
in psoriatics receiving differ ent types of therapy are now be ing 
conducted (personal communication, Dr. Euge ne Farber, Stan-
ford University). 
In addition to the possible ris k of skin cancer, mutagens, and 
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carcinoge'ns conta ined in c rude coal tar may unde rgo percuta-
neous a bsorption a nd affect other sites in the body. Many types 
of organic compounds su ch as those found in coal tar can 
pe netrate the skin and enter systemic circulation [6]. Studies 
with C l45-florouracil indicate that percutaneous a bsorption in 
psoriatic skin may be far greater than in normal skin [7). 
Coal tar m edications have been shown to be mutagenic in 
microgram qua ntities [8] a nd a r ecent r eport on coal tar sham-
poos has indicated that potent carcinogens such as 
be nzo( a) pyrene are indeed present in t hese medications [9). 
To test the hypothesis that mutagenic ch emicals could be 
absorbed through the skin during tar phototherapy, urine ex-
tracts from psoriatics undergoing this therapy were tested for 
mutage nicity in the Ames Salmonella/ Microsome test. 
MATERIALS AND METHODS 
Patients 
Urine samples were collected from 12 nonsmoking and 2 smoking 
patients wi th psoriasis vu lgaris undergoing coal tar photochemotherapy 
and from 4 nonsmoking volunteers (controls). The psoriatic patients 
were either hospital inpatients or receiving outpatient day care therapy 
at University of Cali fornia hospitals at .Los Angeles or San Francisco. 
The severi ty of the psoriasis was quantitatively determined in all Los 
Angeles inpatients: 01 (95%), 1H (75%), MQ (45%), FA (40%), and NX 
(95%). All other subjects (FT, GC, JH, NQ, MK, MN, SF, UJ) except 
NO (San Francisco inpatient) were from the San Francisco Day Care 
Center which requires at least 30% skin involvement for entry in to their 
treatment program. None of the patients from Los Angeles had psoriasis 
in the geni ta l area and Ul'ines were collected under the supervision of 
a nurse. Patients were warned not to contaminate urine containers with 
coal tal' which. might be on their hands. It was not possible to collect 
pretreatment urines from the aforementioned patients. 
San Francisco Day Care patients' urines were collected in the after-
noon after approximately 5 hI' after skin contact with coal tal' prepa-
rations. Most of these patients were also using a tar preparation at 
home overnight. Inpa'tient lIl'ines were collected at the first morning 
micturation a fter the pa tient had slept with a tar prepal'a tion of the 
skin. Urine samples were collected in polyethylene cups .and ranged 
from 30 to 190 ml in volume. Occasionally 2 smaller samples from a 
patient were pooled so that the urine volume passed through a column 
was never less than 75 ml. Samples were frozen shortly after collection 
and stored at -50°C. 
To ensure further that there was no risk of genital and, therefore, 
urine sample contamination from the genital skin, a further study was 
conducted . Two nonpsoriatic nonsmoking volunteers were treated with 
a single application of petrolatu m to their trunk skin a bove the wa ist 
for 6 hr. T hey then received a minimal erythema dose (MED) of UVL 
(Westinghouse FS72 Sunlamp tubed cabinet) . Urine samples were then 
collected over the next 30 hI' to determine whether petro latum plus 
UVL would result in an increase in urinary mutagenesis. 
One week late r, these 2 volunteers received a single application oi' 
5% crude coal tal' (CCT) (USP) in petrolatum to the trunk skin above 
the waist. This remained for 6 hI' and then was removed. It was applied 
and removed by the nursing staff. The volunteers hands were not in 
contact with the tal' and at no time was there any evidence of geni i? l 
skin contamination. One of the volunteers (#2) wore a condom catheter 
that was attached before treatment and worn for 12 hr fo llowing 
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application of the coal tar, again, to remove any risk of genital skin 
contamination. No tar was applied to hands or arms and the trunk skin 
was covered to prevent contamination of hands. 
T hey received a single MED of UVL and their urines were collected 
for the next 30 hr. 
One nonsmoking psoriatic patient, FG, received a single application 
of 5% CCT to the trunk skin above the waist followed by UVL. The 
volunteers and patient FG were taking no other medication for at least 
2 weeks before or during CCT treatment. 
None of the nonsmoking controls were taking any drugs but most of 
the psoriatic patients were under some form of medication. There was 
no medication common to more than 4 of the psoriatic patients with 
hydrochloroth iazide and Dalmane being the most frequently used 
drugs. 
Preparation of Urine Extract for the Mutagenicity Assay 
T he procedures used are similar to those described by Yamasaki and 
Ames [10]. Briefly, urine samples were quickly thawed in a warm bath 
at 45°C to 55°C and cllntrifuged at 5,000 xg for 10 min to remove large 
particulates. The urines were then vacuum flltered th.rough 0.45 um 
GN-6 metricel filters (Gelman Instrument Co., Ann Arbor, MI). XAD-
2 resin was used to concentrate possible mutagens present in the urine. 
Columns were constructed by pouring 1 gm of purified XAD-2 resin 
into disposable polyethylene columns which were plugged with glass 
wool at each end . This gave a resin bed height of 3.2 cm and a bed 
volume of approximately 2.3 cm". Prior to use, columns were washed 
with 30 ml of acetone, followed by 30 rnl of methanol and then 100 ml 
of distilled water. Resin and columns were obtained from Applied 
Sciences Laboratories (State College, PAl. Samples were loaded on the 
XAD-2 columns. The flow rate through the column was lim ited to 2 to 
3 ml/min by a nylon stopcock. After loading, residual urine was expelled 
from the column by a slream of nitrogen. The column was rinsed with 
2 ml of distilled water which was also removed with a stream of 
nitrogen. The absorbed components were then eluted into 18 x 100 mm 
test tubes with 5 ml of acetone. The eluate from each column was 
placed in a warm water bath (60° to 65°C) under a stream of nitrogen 
to fac ili tate evaporation. When the samples were dry, dimethylsulfoxide 
(DMSO) was added to each tube to dissolve the residu e thus forming 
the urine extract. DMSO was added in a ratio of 0.1 ml per 20 ml of 
urine passed through the column. The urine extracts were filter steri-
li zed through 0.2 um FG filters (Millipore Corp., Bedford, MA) before 
being incorporated into the mutagenicity assays. 
Assay of Mu.tagenicity 
Salmonella typhimurium L T2 strain T A 98 was obtained from Dr. 
Bruce Ames (University of California, Berkeley, CAl . The TA98 was 
grown up overnight in modified Tryptone broth [11]; otherwise the 
mu tageQicity assays were performed and rat liver microsomes were 
prepared following Ames' published procedures [12]. Liver was ob-
tai ned from male Sprague-Dawley rats (Hilltop Farms, Chatsworth , 
CAl , wich was induced with Arodor 1254 (Analabs, North Haven, CT) . 
An O. I ml aliquot of urine extract was added to each plate assay. 
Stra in TA98 was used in the assays because it is sensitive to coal ta r 
mutagens. A few init ia l assays were carried out with or without 89 mix 
(consta ining 50 ul S9) and with or without 0.2 mg (approximately 70 
units) of B-glucuronidase with su lfatase aCtivity (type HI from Helix 
pomatia, Sigma, St. Louis, MO) . Later assays contained S9 mix only. 
When counting revertants, special attention was always paid to the 
background lawn growth. Two to 4 plate assays were performed on 
each sample except for patient JH in which most of the extract was 
lost. 
Benzo(a)pyrene was used as a positive control and purchased from 
Ald rich Chemical Co., Milwaukee, WI. 
RESULTS 
Initial experime nts from patient urine extracts were done to 
optimize th e detection of mutagenicity. Table I shows S9 mix 
was necessary to obtain an increase in the revertant response 
with the nonsmokers' (psoriatic and control) urine extracts. 
T h e smoking psoriatic patients' urine extracts were most active 
in the presence of S9 mix but also showed some activity in its 
absence . A few extracts were a lso tested in the presence of B-
glucuronidase. T his had no a pparent effect on the revertant 
response obtained with S9 mix . The data in Table I includes 
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TABLE L Effect of S9 mix" and B ·glucuronidase (with sulfatase 
activity) on urine extract mutagenicity 
Group Subject Wi th S9 mix Without S9 mix 
Strain 30 22 
TA 98 Only 
Control NT 57" 22 
Nonsmoking MK 155 22 
Psoriasis SF 43 6 
Subjects GC 116 31 
Smoking OI 400 113 
Psorias is 
S ubjects IH noo 107 
Subjects S9 & B Glu e. (70 S9 & B Glue. (35 S9 Only uni ts) uni ts) 
FT 50" 49 63 
45 
SF 64 79 73 
62 
UJ 37 37 30 
28 
NT 35 35 35 
50 
IH 213 193 
182 140 
"When testing the effects of S9 mix, equal amounts of a subject's 
urine extract were added to both plates (with S9 and without S9) . The 
amount of extract used varied between subjects. The amoun t was 
sometimes greater or less than 0.1 ml. TA 98 was the mutagen tester 
strain used. 
" His + revertants per plate from 0.1 ml of urine extract. T he spon-
taneous revertants have not been subtracted. 
r esults of 12 plates in which B-glucuronidase was added a nd a ll 
data presented are from assays containing S9 mix. 
The mutage nicity of benzo(a )pyren e was tested in each ex-
perime nt to monitor the activity of the S9 mix and the sensitiv-
ity of t h e mutagen tester strain. The S9 mix used in these 
experiments produced 628 ± 119 (SD) revertants pe r 4 ug 
benzo(a)pyrene using strain TA98. M cCann et al [13] h ave 
reported a revertant count of 548 for 4 ug of benzo(a)pyrene. 
Previous studies by Saperstein and Wheeler [8] showed that 
strain T A98 was most sensitive to the mutagenic effects of CCT 
but a s ignificant increase in his + revertants was observed with 
TA1538 a nd TAlOO. 
Table II sh ows details of subjects, m edication history , urine 
collection data, and th e results obtained from all t h e mutagen-
icity assays of urine extracts. 
T en of 12 nonsmoking psoriatics had at least one mutagenic 
urine that was 3 to lO-fold higher than cont rol urines. Many of 
the psoriatic patients were receiving drugs in addition to crude 
coal tar. The exposure to ultraviolet light a nd/or the non tar 
m edications (or som e interaction between the 2) may possibly 
have contribu ted to t h eir urine mutagenicity. To test this 
hypot hesis 3 of the control subjects volunteered to give a nother 
set of urine samples after receiving ultraviolet light (UYL) 
exposure with a ba nk of 8 FS 4 0 sunla mp tubes (1 MED). 
Samples were ta ken before exposure and at 4 and 24 hr after 
expOSUl"e . One of these subjects (NT) a lso Look D alman e a nd 
hydrochlorothiazide before the UYL exposure. None of the 
samples showed an increase in revertant counts. 
Although stringe nt efforts were m ade to insure that all urine 
samples collected were not contaminated with the therapeuti-
cally a pplied cutaneous CCT, the possibility of it be ing a source 
of mutagenic activity present in the urine was addressed in the 
study of 2 volunteers a nd 1 psoriatic patient, FG. As noted in 
this a ddi t ional study, a ny risks of genital skin contamination 
by the coal tar were removed. 
The F igure shows the excretion of mutagenic compounds in 
urines collected during a nd after s ingle application of pe trola-
tum or 5% CCT. Approximate ly t he same a mount (30G) of 
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TABLE II. Mutagenicity of urine extracts" 
Sampl e mea n a ndSubject 
(SO) " mean 
Subjec t Sample # & Heve rtants/20 ml urine 
Code vo lume 
Medica tio ns 
FT 
CC 
JH 
NQ 
MK 
MN 
MQ 
NO 
S F 
UJ 
NX 
FC 
0 1 
IH 
# 1 
100 1111 
#2 
11 5 1111 
# 1 
11 0111 1 
#2 
100 ml 
#:.1 
120 Illl 
(Pooled from 2) 
# 1 
120 ml 
(Poo led from 2) 
# 1 
90 ml 
#2 
120 ml 
#:.1 
122 ml 
# 1 
140 1111 
(Pooled from 2) 
#2 
125 1111 
(Poo led from 2) 
# 1 
100 ml 
#2 
1001111 
# 1 
IJOml 
#2 
100 ml 
# 1 
130 ml 
#2 
140 ml 
# .1 
130 ml 
#2 
1401111 
# 1 
11 5 ml 
#2 
160 ml 
(pooled from 2) 
# 1 
145 ml 
# 2 
125 1111 
# 1 
IHO ml 
#2 
140 ml 
Nonsmoking Psoriasis S u bjects 
25 ± 8 
92 ± 22 
62 ± 17 
58 ± 13 
92 ± 28 
103(N = I) 
29 ± 3(N = 3) 
5a ± 13 
7 1 ± 24 
11 4 ± 27 
11 0 ± 18 
:.14 ± 1:.1 
70 ± 4 
20 ± 7 
2 1 ± 9 
13 1 ± 42 
190 ± 20 
43 ± 8 
40 ± 12 
7±5 
21 ± 8 
see Table 1!l 
see Figure 
5% CCT in petrolatum 
58 with salicylic acid 
Aspirin 
10% CCT in petrolatum 
with lactic acid . 20% 
LCD in Aquaphor 
71 Di lantin 
10:.1 
5% CeT in petrolatum 
with salicylic acid 
Dalmane 
2 % CCT in pe t rolatu m 
5 1 Hydropres 
11 2 
52 
21 
16 1 
5% and 10% CCT in petro· 
latum 
Dyuzide, aspirin 
2% CCT in petrolatu m 
Dalmane 
1% CCT in petrolatum 
Dyazide. Naproxen. Thy-
l'uxin, aspirin . a ntacids, 
Hiopan 
10% LCD in Niven Oil , AI· 
doril , Aldomet, Atara 
Dalma ne, Tylenol, 
Lomolil t ria mcinolone 
(top ica l), antac ids. 
potassium chl oride 
10% CCT in petrolatum 
42 Ant.hralin, Lidex , Indocin 
10% LCD in Aqu uphor 
1% CCT; aspirin 
5% CCT in petrolatum 
Smoking Psoriasis S ubjects 
IfJ8 ± 14 
228 ± 35 
508 ± 16 
862 ± 403 
2 1:.1 .1 % CCT in pe trolatum 
5% CCT in Aqua phor 
Dalma ne, AWrax. Ben-
685 miry; Valiu m, marijuana 
(smokes) (ma rijuana 
not prescribed by phy· 
sicia n) 
" Patie nt data (I'everta nts/ plate) fo r each subject's urine sam ples a re shown 
here. The backgrou nd of 26 ± 6 (, D) reve rtan t/p late obta ined with TA 98 plus 
S9 has been suhtracted from mutagenicity datu . CCT crude coal Wr, LCD, liquor 
ca rbonis detergens. All patie nts were rece iving ultraviolet light B. 
I. Mean of II assay.!) unl ess othe rwise noted. 
Sub· 
jects 
NT 
EB 
JI{ 
MX 
w 500 
z 
II: 
:::J 
E 
0 
N 
"-
300 
(J) 
I-
Z 
~ 
I-
II: 
W 
> 
W 
II: 100 
+ (J) 
:x: 
TABLE II -conlinued 
# 1 
140 onl 
#2 
100 ml 
#:.1 
135 ml 
# 1 
80 onl 
# 1 
80 onl 
#2 
100 ml 
# 1 
IJO ml 
#2 
75 ml 
1111111111111111111111111 
Control Subjects 
12 ± 8 
28 ± 6 
30 ± 3 
IG ± 4 
13 ± 4 
8±G 
16 ± 4 
14 ± 7 
23 
16 
II 
15 
.----.. ~ \ . 
-------. 
-----. 
- 2 0 10 20 30 
HOURS 
FIG l. Mutage nic activ ity of urines after single a pplication of p et ro-
latum o r 5% c rude coa l tar (eel') and UVL light treatm e nt. For details , 
see " Materia l and Methods." Volunteer I, . ; volun teer 2 • (wore a 
condo m cath eter) ; patient FG, .... A brohen line (- - -) indicated 
treatme n t with petrolatum plus UVL a nd a solid line (- ) indicates 
treatme nt with 5% eel' p lus UVL. The duration that petrolatum or 
5% eel' remaine d o n t h e s kin , is indicated by t h e horizontal line. 
petro latum or eeT was applied to a similar surface area for 
each volunteer a nd -patient FG. No mu tagenicity activity was 
detect.ed in mines after petrolatum and UVL treatment. Mu-
tagenic activity was readily observed in volunteers 1, ,2, and FG 
within hours of applying the tar. A peak in activity was observed 
between 6 and 8 hr after application. The peak number of 
his + r evertants per 20 ml of urine was 426, 453, and 496 for 
volunteer 1, 2, a nd FG respectively. The mutagenic activity was 
rapidly eliminated with almost no activi ty detectable by 30 hl'. 
Samples collected between 30 and 72 ill' were negative for 
volun teers 1 and 2. These data clearly demonstrate the percu-
taneous absorpt ion and subseq uent excretion of mu tagens from 
5% eeT. 
All t he urine extracts from controls and psoriatic patients 
produced a n increase in the number of revertants over t.he 
background level of 26 ± 6 (SD) revertants per plate obtained 
with TA98 and S9 alone. The average response was 16 revert-
ants/plate (subject averages) over background . In the present. 
study, columns were washed with distilled water before t he 
acetone elution to reduce histidine contamination of the urine 
extract. This procedure was suggested but not performed by 
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Yamasaki and Ames [10]. Since histidine bioassays were not 
performed on the urine extracts, the cause of the increased 
revertant response in controls remains unclear. Aside from 
histidine contamination, it is possible that small amounts of 
mutagens may be formed during the evaporation procedure or 
that there are small amounts of endogenously produced muta-
gens in human ill'ine. There has recently been a report on the 
detection of mutagens in normal human feces [14], so that latter 
possibility should not be ruled out too quickly. The dependence 
of the revertant response on S9 activation indicates that histi-
dine contamination is not responsible for the observed activity. 
Revertants were picked from several plates containing urine 
extracts and streaked on Vogel-Bonner media with no histidine 
to demonstrate that they were true histidine prototrophs. 
Table II also shows that there was greater variability between 
subject averages and sample averages in the psoriatic subjects 
than in the control group. For some patients, some samples 
were clearly mutagenic while others were not (FT, KQ, MN). 
This variability is not surprising since the rate of chemical 
excretion will likely vary during the day and the specimens 
collected were essentially random samples of the patients' daily 
urine output. There was no control placed on daily fluid intake 
or the time of other micturations before or dwing tar therapy. 
To compare the revertant response of the nonsmoking con-
trols with that of the nonsmoking psoriasis patients, the data 
(results of individual plate assays) for each of a subject's sam-
ples were averaged to obtain sample means. The sample means 
of a subject were then averaged to obtain a subject mean. 
S ubject means from the 4 controls and the 10 nonsmoking 
psoriasis subjects were then compared by a t-test using separate 
variance estimates for each group [15,16]. This test showed that 
the mean of the psoriatic patient group was significantly higher 
(p < .01) than the mean of the control group. 
While the group mean of the psoriatic patients was signifi-
cantly elevated above that of the controls, there are psoriatic 
patients (MO and UJ) whose sample means fall within the 
range of response of the control subjects. 
For most pati'ents it was difficult to get a sample before the 
start of the crude coal tar regimen and daily samples for any 
extended period of time. However, we were able to follow 
patient NX for 2 weeks. Table III shows the excretion of 
mutagens before treatment and for 2 weeks during crude coal 
tar therapy. Initially, evening (PM) samples tended to be higher 
than morning (AM) samples but after approximately 1 week the 
TABLE III. Mutagenicity of urine e;'(tracts froln. patient NX before 
and during a 2-weell course of treatment with crude coal tar and 
ultraviolet light" 
Day His ·' /20 ml of urine" 
Pre Rx-O 2 
1 122 
2-PM 75 
5-AM" 9 
PM 16 
6-AM 48 
PM 143 
PM 83 
7 87 
8- AM 5 
PM 84 
PM 121 
lO-PM 37 
ll-AM 89 
12-AM 143 
PM 150 
14-AM 95 
PM 70 
n Treatment consisted of 1% crude coal tar USP in evening, a 
Balnetar bath in the morning and UVL within 2 hr every day. 
b Mean number (N = 2 to 4) of revertants per 20 ml of urine. A 
background of 26 revertants was subtracted. 
" No coa l tar or UVL treatment was given on day 5. 
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mutagenicity of urines stabilized between 96 and 175 revertants 
per 20 ml of urine. 
DISCUSSION 
Many dermatologists feel that tar medications and ultraviolet 
light are safe even though coal tar has been shown to be 
carcinogenic in animals. As noted earlier, there is some conflict 
in regards to whether the incidence of skin cancer is higher in 
psoriatic patients [4,5]. More complete epidemiological studies 
are now underway to examine the incidence of all types of 
cancer in psoriatic patients with respect to their treatment 
histories and skin types (personal communication; Eugene Far-
ber, Stanford University, CAl. 
The mutagenicity ofthe urine extracts from psoriatic patients 
·undergoing tar photochemotherapy indicates that the effects of 
the coal tar may not be limited to the skin. The possibility that 
drugs and/or ultraviolet light other than crude coal tar are 
responsible for the mutagenesis is not supported by the data 
from the volunteer control exposed to UVL with and without 
hydrochlorothiazide and Dalmane. Both of the aforementioned 
drugs are not mutagenic in the Ames/microsome assay [17]. 
Other drugs such as aspirin [18], reserpine [19]; Indocm [18], 
phenacetin [20], Valium [17] and naproxen (personal commu-
nication, Syntex-Corp.) are not mutagenic in the Ames test. 
Anthralin is questionable in the Ames test due to its bactericidal 
properties [21]. Minnich V et al [22] screened the urines of.a 
large population of hospital patients (1,010) for mutage?lC 
activity with the non plasmid containing Ames tester strams 
TA1535, TA1536, TA1537 and TA1538. Only patients receiving 
cancer chemotherapeutic agents and metronidazole were posi-
tive. The following mugs were among those that had been 
administered to hospital patients and were tested in vitro in 
the Ames test and found to be negative: Aldomet, Benadryl, 
Dalmane, Dilantin, L-Dopa, Riopan, Tylenol, and Valium. 
In a previous study Saperstein and Wheeler [8] found that a 
positive mutagenic response could be obtained with less than 
100 ug coal tar. With many coal tar medications in clinical 
practice, several hundred times the aforementioned dose .may 
be applied to psoriatic skin. Therefore, it appears very hkely 
that the mutagenic activity in the psoriatic patient's urine 
extracts is due to percutaneously absorbed mutagens and/or 
carcinogens from coal tar medications. This therapy may, there-
fore, represent a mutagenic and carcinogenic risk to other parts 
of the body. However, it may not be wise to depend only on 
skin cancer data when assessing the risks of coal tar medica-
tions. It should also be remembered that psoriatic skin is not 
normal and it may possibly have certain protective capabilities 
against cancer [23]. These may not be found in normal skin or 
other tissues of the body. 
Psoriatic patients who smoked had the most mutagenic ex-
tracts of all the subjects. Smoking may have an additive or 
synergistic effect on mutagen excretion in the coal tar exposed 
subjects. Cigarette smoke condensate is known to be mutagenic 
in vitro [21]. Yamasaki and Ames [10] examined the urines of 
10 cigarette smokers (who smoked 15 to 44 cigarettes per day) 
for mutagenicity. Seven had mutagenic urines with the number 
of revertants/25 ml ranging from 40 to 300. Considering the 
difference in dose (gm of tar to ug of smoke condensate) and 
route of administration (percutaneous vs_ inhalation) it is Sill'-
prising that the urines of psoriatics treated with coal tar are not 
more mutagenic. 
The relationship between the mutagenic and carcinogenic 
components of coal tar and those components which are re-
sponsible for its therapeutic benefits need to be examined. It is 
only with this type of information that dermatologists can begin 
to compare adequately the risks of coal tar therapies with the 
other therapies at their disposal. Hopefully, this information 
will also lead to the development of safer and effective tar 
therapies. 
An important question to consider is whether the risks of tar 
medications and therapy outweigh their therapeutic benefits. 
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Although psoriasis is not usually a life-threatening disease, it 
can be physically and socially disabling. Coal tar regimens have 
been used for psoriasis treatment for many years but perhaps 
the patients have been inadequately foll owed for too short a 
time. A recent close scrutiny of psoralen photochemotherapy 
patient in one study showed an increase in some patient groups 
of cutaneous squamous cell cancers [24]. Similar studies should 
ideally be performed on psoriatic patients receiving other treat-
ment modalities. It should be noted that only a small minority 
of people with psoriasis undergo tar photochemotherapy regu-
larly and this may be for only a few weeks each year or less. 
However, nonprescription tar medications have a much wider 
usage since they al'e indicated for many common forms of 
dermatitis . Some consumers might use these medications quite 
often throughout their lives. 
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